TREVI THERAPEUTICS INC (TRVI)

What TREVI THERAPEUTICS INC does

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio (oral nalbuphine ER), an investigational therapy for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Haduvio acts on the cough reflex arc as a kappa receptor agonist and mu receptor antagonist (KAMA), targeting opioid receptors critical to cough control. The company recently achieved positive Phase 2b results and is advancing two parallel Phase 3 trials with FDA alignment on the development path toward a potential New Drug Application submission.

Fundamentals

• Price$18.40 as of 2026-07-09 close
• Market cap$2.6B as of 2026-07-10
• 1-year return+217.5% as of 2026-07-09 close
• ROE-24.5% as of 2026-07-10
• Debt / equity0.00 as of 2026-07-10
• Beta1.03 as of 2026-07-10

Ask why TRVI looks like this →

Key risks (from latest filing)

["Clinical development risk: Phase 3 trials may fail to demonstrate efficacy or acceptable safety profile, preventing FDA approval and commercialization of Haduvio","Regulatory risk: FDA may not accept the proposed Phase 3 trial designs or may impose additional requirements that delay or complicate the NDA pathway","Funding risk: The company is pre-revenue and burning cash; additional capital will be required to fund Phase 3 trials and commercialization, which may be dilutive to shareholders"]

See TRVI's biggest risks from its latest 10-Q →